A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software

Sponsor
Chang Gung Memorial Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05903313
Collaborator
(none)
4,306
1
1
5.4
799.2

Study Details

Study Description

Brief Summary

"Chang Gung ECG Abnormality Detection Software" is a is an artificial intelligence medical signal analysis software that detect whether patients have abnormal ECG signals of 14 diseases by static 12-lead ECG. The 14 diseases were

  • Long QT syndrome

  • Sinus bradycardia

  • Sinus Tachycardia

  • Premature atrial complexes

  • Premature ventricular complexes

  • Atrial Flutter, Right bundle branch block

  • Left bundle branch block

  • Left Ventricular hypertrophy

  • Anterior wall Myocardial Infarction

  • Septal wall Myocardial Infarction

  • Lateral wall Myocardial Infarction

  • Inferior wall Myocardial Infarction

  • Posterior wall Myocardial Infarction

The main purpose of this study is to verify whether "Chang Gung ECG Abnormality Detection Software" can correctly identify abnormal ECG signals among patients of 14 diseases. The interpretation standard is the consensus of 3 cardiologists. The results of the software analysis will be used to evaluate the performance of the primary and secondary evaluation indicators.

Detailed Description

Detailed procedure:
  1. Sample source:

This is a retrospective study, and the data comes from the Chang Gung Medical Research Database(CGRD) which was an database form 6 hospitals of Chang Gung Memorial hospital. We collected de-identified static 12-lead ECG data from the database during 2006.01.01~2019.12.31, and the length of the ECG was 10 seconds.

  1. Sampling:

In this experiment, the training dataset and the test dataset ECG were separated. Afterwards, the ECG signals are stratified according to the distribution as the test sample, and all abnormal ECG signals of 14 diseases will be independently sampled from the ECG database of the test set.

  1. Confirmation criteria:

The ECG data will be preliminarily screened and selected by the inclusion and exclusion criteria and compiled serial numbers. Then, a cardiologist confirms that the sampling results of the ECG data do not include the exclusion criteria again.

  1. Physician interpretation:

The ECG data will be converted into graphic files and submitted to 3 cardiologists for interpretation abnormal ECG signals of 14 related diseases. The results will be used as the standard of this study (Reference).

  1. Software interpretation:

After confirming the test standard, input the ECG signal into Chang Gung ECG Abnormality Detection Software to analyze abnormal ECG signals of 14 diseases and interpret each ECG data.

  1. Statistical analysis:

After the software interpretation is completed, it will be compared with the results of the physician's interpretation and analyze the primary and secondary evaluation indicators.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
4306 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
The investigators collected retrospective data and gave to the software to interpret. 3 cardiologists' interpretation was the gold standard. The study would test whether the software could correctly interpret left ventricular systolic dysfunction.The investigators collected retrospective data and gave to the software to interpret. 3 cardiologists' interpretation was the gold standard. The study would test whether the software could correctly interpret left ventricular systolic dysfunction.
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Anticipated Study Start Date :
Jun 29, 2023
Anticipated Primary Completion Date :
Nov 8, 2023
Anticipated Study Completion Date :
Dec 10, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Software diagnosis

Software diagnosis with gold standard of 3 cardiologists' interpretation.

Drug: Chang Gung ECG Abnormality Detection Software
This device is expected to be used for the static 12-lead ECG to detect whether there are abnormal ECG signals related to diseases and outputs the results.
Other Names:
  • CGMH-EAD-001
  • Outcome Measures

    Primary Outcome Measures

    1. Sensitivity and Specificity [baseline]

      The rate of test results that correctly indicate the presence and absence.

    Secondary Outcome Measures

    1. Area Under the receiver operating characteristic Curve [Baseline]

      A graphical plot that illustrates the diagnostic ability of a binary classifier system as its discrimination threshold is varied.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Equal or greater than twenty years old.

    • Static 12-lead electrocardiogram of General Electric MUSE XML format file.

    • The data comes from the static 12-lead electrocardiogram device of General Electric (model MAC5500).

    • The electrocardiogram signal is 500 Hz.

    • The Alternating current (AC) filter of the electrocardiogram signal is 60 Hz.

    • The resource of original diagnosis was a cardiologist.

    Exclusion Criteria:
    • Cases used in the model development process.

    • Lacks any electrode.

    • Contain any electrode lacks a segment.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Chang Gung memorial hospital Taoyuan city Taiwan 333

    Sponsors and Collaborators

    • Chang Gung Memorial Hospital

    Investigators

    • Study Chair: Chang-Fu Kuo, MD/Ph.D, Associate Professor and Director Division of Rheumatology

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Chang Gung Memorial Hospital
    ClinicalTrials.gov Identifier:
    NCT05903313
    Other Study ID Numbers:
    • 202300710A5
    First Posted:
    Jun 15, 2023
    Last Update Posted:
    Jun 15, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 15, 2023